ReviewInternational journal of molecular sciences2024
Immunoassays: Analytical and Clinical Performance, Challenges, and Perspectives of SERS Detection in Comparison with Fluorescent Spectroscopic Detection.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07337499 (Comparison of the Maglumi X3 SNIBE Method With Other Analytical Methods in Laboratory Medicine), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Maglumi X3 SNIBE Method With Other Analytical Methods in Laboratory Medicine
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Catch-and-display immunoassay for digital biomarker detection.Nanoscale horizons · 2026Article
- Application of Core-Shell Bimetallic Nanoparticles with Polydopamine-Assisted Nanogap in SERS-Based Lateral Flow Immunoassay of Prolactin.Sensors (Basel, Switzerland) · 2026Article
- SERS and SEF with enhancement in nanogaps: from fabrication to biosensing.Nanoscale advances · 2026Review
- High reliability Ag/Ni/NiO nanowire-based SERS for cancer detection: a study on breast cancer.Nanoscale advances · 2026Article
- Catch-and-Display Immunoassay as an Accessible Platform for Digital Biomarker Detection.bioRxiv : the preprint server for biology · 2026Article
- Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025Review
- A Review of High-Sensitivity SERS-Active Photonic Crystal Fiber Sensors for Chemical and Biological Detection.Sensors (Basel, Switzerland) · 2025Review
- Intelligent molecular logic computing toolkits: nucleic acid-based construction, functionality, and enhanced biosensing applications.Chemical science · 2025Review
- Advances in methods for rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Review
- Detection of Biomarker Clusterin in SERS Immunoassays on Al Foil After Substrate Selection and Assay Optimization with Fluorescently Labeled Antibodies.Molecules (Basel, Switzerland) · 2025Article
- Noble Metal-Based Nanocomposites for Surface-Enhanced Raman Spectroscopy Detection of Food Contaminants.Foods (Basel, Switzerland) · 2025Review
- Precision oncology through SERS: emerging approaches for improved cancer diagnosis and prognosis.Nanomedicine (London, England) · 2025Article
- Innovative applications of silicon dioxide nanoparticles for targeted liver cancer treatment.Frontiers in bioengineering and biotechnology · 2025Review
- Establishment of an indirect ELISA detection method for porcine reproductive and respiratory syndrome virus NSP4.Frontiers in microbiology · 2025Article
- A comprehensive review on the pretreatment and detection methods of nitrofurans and their metabolites in animal-derived food and environmental samples.Food chemistry: X · 2024Review
- Fluorescence Immunoassay of Prostate-Specific Antigen Using 3D Paddle Screw-Type Devices and Their Rotating System.Biosensors · 2024Article
- Evaluation and Limitations of the Novel Chemiluminescent Enzyme Immunoassay Technique for Measuring Total Tau Protein in the Cerebrospinal Fluid of Patients with Human Prion Disease: A 10-Year Prospective Study (2011-2020).Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunoassays (IAs) with fluorescence-based detection are already well-established commercialized biosensing methods, such as enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay (LFIA). Immunoassays with surface-enhanced Raman spectroscopy (SERS) detection have received significant attention from the research community for at least two decades, but so far they still lack a wide clinical commercial application. This review, unlike any other review that we have seen, performs a three-dimensional performance comparison of SERS IAs vs. fluorescence IAs. First, we compared the limit of detection (LOD) as a key performance parameter for 30 fluorescence and 30 SERS-based immunoassays reported in the literature. We also compared the clinical performances of a smaller number of available reports for SERS vs. fluorescence immunoassays (FIAs). We found that the median and geometric average LODs are about 1.5-2 orders of magnitude lower for SERS-based immunoassays in comparison to fluorescence-based immunoassays. For instance, the median LOD for SERS IA is 4.3 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.